Posted by Michael Wonder on 01 Sep 2022
PBS listing for ovarian cancer and kidney disease
1 September 2022 - From 1 September 2022, Australians will have access to new and expanded medicines on the Pharmaceutical Benefits Scheme, including treatments for ovarian cancer, leukaemia, chronic kidney disease and spinal muscular atrophy in children.
Niraparib (Zejula) will be listed for the first time to treat ovarian, fallopian tube, or primary peritoneal cancer.
